The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
about
Pharmacologic resistance in colorectal cancer: a reviewIntrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesDesign and analysis of a Petri net model of the Von Hippel-Lindau (VHL) tumor suppressor interaction networkSwitching off malignant mesothelioma: exploiting the hypoxic microenvironmentCetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.Erlotinib-Conjugated Iron Oxide Nanoparticles as a Smart Cancer-Targeted Theranostic Probe for MRIA phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.Antivascular therapy for epithelial ovarian cancer.Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidinesDrug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model.Integrated analysis identifies interaction patterns between small molecules and pathwaysDietary flavonoid and lignan intake and breast cancer risk according to menopause and hormone receptor status in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study.Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via Nuclear Factor-KappaB Signaling.Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.New trends in epidermal growth factor receptor-directed monoclonal antibodies.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancerCombined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growthDelphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.Targeting tumor cell motility to prevent metastasis.Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt.ZEPHYR: failure of a "spring wind" in lung cancer.ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients.Complex prolactin crosstalk in breast cancer: new therapeutic implicationsN⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.Effects of epidermal growth factor receptor kinase inhibition on radiation response in canine osteosarcoma cells.Application of GQSAR for Scaffold Hopping and Lead Optimization in Multitarget Inhibitors.Insulin growth factor 1 like receptor (IGF-1R).Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.EGF-Induced VEGF Exerts a PI3K-Dependent Positive Feedback on ERK and AKT through VEGFR2 in Hematological In Vitro Models.Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
P2860
Q26769850-356C820E-1B1E-4C74-8C13-D7C883811D31Q27002547-405B557D-62CF-44A8-B9CD-2BAD68911DEEQ27333673-EBCDEA3A-DC2D-463B-9D4C-C45157253BDAQ29248727-7E0EF0B8-0BF9-403F-8143-E0661041C8B8Q30557865-454CB56F-523C-4D6F-ABEC-043FB996F7F3Q30828291-DC47C633-BB83-42BC-8343-7F7457B4D259Q33401450-9695701D-CEDE-40A6-9C53-B5EB759FA04DQ33412909-996FCCC2-3EE9-4A09-9097-A8241E08A0E4Q33421361-CAA96C35-AFA1-40A3-99AC-E457AB620C55Q33429478-16A7D2E6-0E19-4AB0-879D-E40052CE2C11Q33583598-80F47DF5-EE62-4A81-8F2E-8DEDA5AABF75Q33675186-FAC9EDFC-1A36-47F6-A200-53078329D35AQ33835807-30F6FEAB-FDA0-4748-81C4-25709F3255E3Q33938441-64A0E721-AC73-42B5-B782-E4E254E09C5BQ33973363-9A163401-8257-46B9-BBB8-5437D98E1991Q33999789-19270161-DB91-4F3D-AB53-C63201646430Q34036279-BFE2A0F2-A3AE-4E90-B4ED-DB4D0D895959Q34127857-9FBD3403-FE45-4607-AEBC-52E8389B4E86Q34509669-6D222311-CDDA-4FA4-996E-53C67C54F9FCQ34538361-A7EA5D9A-4361-445A-8351-848E246224B1Q34581970-C8452457-6F82-4698-ADFD-EF647621946DQ34621577-0C0B93FD-1189-496E-BA79-2D8C1F336C68Q34704781-BCE96109-052C-4D8A-925D-EBD05A293973Q34781970-725A9D29-8286-48D6-81C5-78F99F076530Q34812100-FEE9840A-F1D7-475B-BD2A-E552F0B6DEC6Q35017125-3DEA4A7E-B9EA-4C5C-9084-6AFC61EF04B6Q35078518-6DBF6296-642A-4B2F-AEC6-BE194AB9B654Q35095152-E3B1F011-A7D7-43DD-A072-9BF186A863D5Q35167467-D8266A06-4326-44DE-B9E5-D28EF0DD53EBQ35200470-0D49C723-E9DE-4984-B4D2-83A90A4BB17AQ35200483-FEED796C-11D0-4352-91AD-A1B7E594EC3FQ35303180-333C7550-CA74-412C-A178-4E3220F5A86FQ35848191-E5CFAD72-4BF0-473D-B614-44777093F911Q36032533-5FFD447D-16B8-458F-B721-EB75573AFF65Q36034972-1AF1B531-B721-4A64-A162-4C223B80DB87Q36091289-329D59CA-F686-408B-B114-38CEDBB896F3Q36157136-011D5A8B-14BB-4E64-B6E4-39FA5E518130Q36160774-72D12C5E-657B-4DBB-BB38-68AFBAEA49CEQ36180362-2E928DB5-F014-431A-AF05-81FAD56708C8Q36243533-83F0A0AF-E1E5-4394-9F90-4000900E0505
P2860
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The role of VEGF and EGFR inhi ...... nti-VEGF and anti-EGFR agents.
@ast
The role of VEGF and EGFR inhi ...... nti-VEGF and anti-EGFR agents.
@en
type
label
The role of VEGF and EGFR inhi ...... nti-VEGF and anti-EGFR agents.
@ast
The role of VEGF and EGFR inhi ...... nti-VEGF and anti-EGFR agents.
@en
prefLabel
The role of VEGF and EGFR inhi ...... nti-VEGF and anti-EGFR agents.
@ast
The role of VEGF and EGFR inhi ...... nti-VEGF and anti-EGFR agents.
@en
P1476
The role of VEGF and EGFR inhi ...... anti-VEGF and anti-EGFR agents
@en
P2093
Josep Tabernero
P304
P356
10.1158/1541-7786.MCR-06-0404
P577
2007-03-01T00:00:00Z